BusinessEmergent BioSolutions Announces Successful Completion of Mutual Recognition Procedure for Market Authorization of BioThrax in European CountriesBy Nasdaq OMXApr 12, 2018, 10:30 AM UTC
BusinessEmergent BioSolutions Announces Executive Management Changes That Enhance Execution of Company’s Growth StrategyBy Nasdaq OMXMar 26, 2018, 8:30 PM UTC
BusinessEmergent BioSolutions to Release Second Quarter 2017 Financial Results and Conduct a Conference Call on August 3, 2017By Nasdaq OMXJul 20, 2017, 11:00 AM UTC
BusinessEmergent BioSolutions to Hold Annual Meeting of Stockholders Thursday May 25, 2017 at 9:00 AM EDT; Webcast Will be AvailableBy Nasdaq OMXMay 11, 2017, 11:00 AM UTC
BusinessEmergent BioSolutions to Release First Quarter 2017 Financial Results and Conduct a Conference Call on May 4, 2017By Nasdaq OMXApr 20, 2017, 11:00 AM UTC
BusinessEmergent BioSolutions Reports Third Quarter and Nine Months 2016 Financial ResultsBy Nasdaq OMXNov 7, 2016, 9:15 PM UTC
BusinessEmergent BioSolutions to Release Third Quarter 2016 Financial Results and Conduct a Conference Call on November 7, 2016By Nasdaq OMXNov 1, 2016, 11:00 AM UTC
BusinessEmergent BioSolutions Awarded BARDA Contract for Advanced Development and Delivery of NuThrax, a Next Generation Anthrax Vaccine, Valued at Up to $1.6 BillionBy Nasdaq OMXSep 30, 2016, 1:04 PM UTC
